



## Controversy

## Challenges in the treatment of gastric cancer in the older patient

Nalinie Joharatnam-Hogan, Kai Keen Shiu, Khurum Khan\*

Gastrointestinal Oncology, Department of Medicine, University College London NHS Foundation Trust, 250 Euston Road, London NW1 2PG, UK



## ARTICLE INFO

## Keywords:

Gastrointestinal cancer

Elderly

Esophageal

Gastric

Colorectal

## ABSTRACT

Gastric cancer is considered an age-related disease, with the majority of new cases in the UK diagnosed in individuals over the age of 75. At present most guidance related to the management of gastric cancer is based on trials undertaken in the fit, younger patient. Historically the elderly have been underrepresented in clinical trials, which frequently have a restricted inclusion to an upper age limit of 75. The European Society for Medical Oncology (ESMO) recommends use of a geriatric assessment to determine functional age when initiating treatment in elderly patients with gastric cancer, which has been shown to be a better predictor of treatment response than chronological age. The physiological changes that occur with age, including reduced organ function and pharmacokinetic and pharmacodynamic variability, together with impaired functional status, necessitate a more individualised approach to treatment decisions in the older patient to provide them with the same advantages from radical treatment and palliative chemotherapy as younger patients. This review summarises the current evidence extrapolated from trial data on how best to optimise treatment for elderly patients with gastric cancer.

## Introduction

Age is one of the biggest risk factors for cancer, and most solid tumours are considered age-related diseases. In the UK, more than a third of all new cancer diagnoses each year are in people aged 75 years and over, and the number of older people living with cancer is set to treble from 2010 to 2040 [1]. Gastro-oesophageal cancers account for 13.5% of all cancer mortality worldwide [2] and remains a huge contributor to the global burden of cancer [3]. It is largely a disease of the older person, with incidence rates in the UK highest in people aged 85–89 [4]. Current guidelines for the management of gastric cancer are predominantly based on evidence from clinical trials frequently performed in younger patients, however the older cancer patient has been shown to have poorer overall survival (OS) outcomes [5]. This review summarises the evidence available for treating the older patient with gastric cancer, to help guide a more individualised approach to their management.

## Disease biology of older patients with gastric cancer

Five year overall survival in older adults with gastric cancer has been shown to be significantly lower than their younger counterpart (29.4% versus 32.9%,  $p < 0.001$ ), which may be secondary to reduced

receipt of standard recommended treatment modalities, but also in part due to possible differences in disease biology [6,7]. There has been shown to be a male predominance in the elderly patient with gastric cancer, compared to a 1:1 gender split in the young [8], with cancers of the distal third of the stomach and well/moderately differentiated cancer more common than in younger age groups [7,9,10]. Histologically, elderly gastric cancer patients mainly have an intestinal type of tumour [11] by Lauren's criteria, and more typically papillary adenocarcinoma by the 2010 WHO classification [12]. These cancers have frequently been shown to metastasise to the liver, with peritoneal metastases less common [13]. Gastric cancers in those of a younger age however, have been suggested to be a more aggressive phenotype, with a higher prevalence of linitis plastica or diffuse type cancer, which have an associated poor prognosis. The differences in disease biology therefore may not play a significant role in accounting for the lower survival seen in the elderly, although the evidence for the effect of disease biology on age and survival have been contradictory [14]. It is also important to note that most studies comparing the clinic-pathological characteristics of gastric cancer patients by age have been conducted in Asia.

More generally progressive physiological changes occur with increasing age, including an impairment of organ function and body composition, with possible effects on the pharmacokinetics and

\* Corresponding author at: Honorary Associate Professor and Consultant Medical Oncologist, University College London Hospital, UCL Cancer Institute and North Middlesex University, London NW1 2BU, UK.

E-mail address: [khurum.khan1@nhs.net](mailto:khurum.khan1@nhs.net) (K. Khan).

<https://doi.org/10.1016/j.ctrv.2020.101980>

Received 6 January 2020; Received in revised form 4 February 2020; Accepted 5 February 2020

0305-7372/ © 2020 Elsevier Ltd. All rights reserved.

pharmacodynamics of anticancer therapies, and a theoretical increased risk of toxicity [15]. A large proportion of the elderly present with comorbidities, which pose the challenge of a potential higher risk of complications from surgery or systemic therapies. Therefore, with an increasingly ageing population, a better understanding of how best to treat elderly patients with gastric cancer is required.

### Identifying frail older patients

Huge variability exists amongst those traditionally defined as old, with chronological age a poor predictor of frailty or fitness. Functional age may be a better prognostic and predictive marker of treatment response, and may improve the treatment decision-making process than reliance on chronological age alone [16].

The Comprehensive Geriatric Assessment (CGA) is an established, validated score of functional status in both the geriatric and oncological settings. It has been shown to identify frail, vulnerable patients at risk of morbidity or mortality [17], taking into account comorbidities, cognitive impairment, functional difficulties and social circumstances, and therefore can help to risk stratify patients when making clinical decisions [18]. Studies have shown that use of a geriatric assessment (GA) tool can influence oncological treatment decisions by 40–50% [19,20], including choice of chemotherapy regime. The CGA has been criticised for the time and resource intensity required to complete it, however shorter frailty tools, including the vulnerable elders survey-13 (VES-13) and geriatric 8 (G8), have been developed to identify patients at risk [21]. The vulnerable elders survey (VES-13) is a 13-item self-administered scoring tool, which considers age, self-rated health, limitations in physical function and functional disabilities, to identify individuals over the age of 65 considered vulnerable. Individuals scoring 3 or more are considered vulnerable, and have been demonstrated to have a 4.2 times increased risk of death or functional decline over a 2 year period compared to those with a score of  $< 3$  [22]. The eight item G8 questionnaire covers multiple domains of cognition, depression, comorbidities, nutrition and disability, scoring individuals between 0 and 17, and has been shown to be a simple and useful tool to adequately screen elderly patients who may benefit from a CGA (scores of  $\leq 14$ ) [23]. The International Society of Geriatric Oncology (SIGO) have highlighted that geriatric assessments can predict the risk of severe treatment-related complications and overall survival in a number of tumours, although there is no current consensus on which GA tool to implement [24]. In the setting of a busy clinical practice, use of brief screening tools such as VES-13 or G8, are recommended to identify vulnerable patients who may benefit from a more comprehensive assessment [25].

A meta-analysis of 6 studies including 1,037 participants found that comorbidity, polypharmacy and activities of daily living (ADL) dependency components to the CGA were predictive factors for post-operative complications in gastrointestinal cancer patients (with cognition, nutritional status, depression and instrumental ADLs showing no conclusive relationship) [26]). There have been limited studies evaluating the role of a GA in predicting outcomes specifically in gastro-oesophageal cancers, with most small retrospective cohort studies [27]. The largest of these reviewed 279 patients, in a single US centre, who had undergone gastrectomy for adenocarcinoma and in whom a GA had been performed within 30 days of surgery. Functional status measured by performance status (PS) greater than zero (OR 2.3, 95% confidence interval (CI) 1.2–4.6), polypharmacy of  $\geq 5$  medications (OR 2.4, 95% CI 1.1–5.2) and pain score  $> 0$  (OR 3.8, [1.6–8.7]), were found to be predictive of major postoperative morbidity [28]. The European Society for Medical Oncology (ESMO) recommends use of a geriatric assessment to determine functional age when initiating treatment in elderly patients with gastric cancer, rather than sole consideration using PS, which may not have much greater ability to predict chemotherapy tolerance than chronological age [29].

### The management of the older patient with gastric cancer in the radical setting

#### Surgery

The main stay of potentially curative treatment for locally advanced gastric cancer is surgical resection, although the vast majority of patients still relapse. Very early T1a staged gastric cancers typically undergo endoscopic resection, either by an endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) [29]. However a more multidisciplinary combined modality approach to treatment is essential to improve prognosis in cancers staged  $> 1B$  [29]. Radical gastrectomies are associated with a high risk of morbidity, and therefore careful selection of appropriately fit candidates is essential. As overall life expectancy continues to rise, opportunities for treatment of elderly patients increase.

Currently an assessment of exercise tolerance, such as cardiopulmonary exercise testing (CPEX), together with review of comorbidities, provides a good indication of perioperative risk and post-operative morbidity. Scoring systems like the American Society of Anaesthesiologists (ASA) physical status score allows stratification of patients prior to a gastrectomy to determine suitability for surgery. The Charlson Comorbidity Index (CCI) is a validated numerical measure of the burden of chronic disease, originally developed to predict prognosis of patients with comorbidities. The age-adjusted CCI (ACCI) has been demonstrated to predict the incidence of postoperative complications following radical gastrectomy for gastric cancer, with a high ACCI score an independent risk factor for the long-term prognosis of gastric cancer patients after surgery [30]. This could prove a useful measure in the decision to undergo surgery and to plan the therapeutic strategy by the multidisciplinary team. A number of risk models have been developed, using data from national databases in Japan ( $n = 20,000$ – $33,000$  gastric cancer cases), including age, ASA, ADL dependency and haematological/biochemical variables to predict surgical outcomes following gastrectomy and therefore appropriateness for surgery [31,32], and validating these or similar models in the Western world could be a useful tool to risk stratify these patients.

Sub-group analyses of data from prospective randomised trials conducted in Western countries of surgical resection of gastric cancer have suggested poorer survival in older patients. The MRC study comparing D1 (limited lymph-node dissection) and D2 (extended lymphadenectomy) resections found that 5 year survival in those patients over 60 was significantly worse than those under 60 (hazard ratio (HR) 1.03, 95% CI 1.01–1.04,  $p = 0.0001$ ), with similar results in those aged 60–69 and those over 70 [33]. In an Italian trial, irrespective of type of resection (D1 or D2), a similarly increased HR for survival was seen in those patients aged 70 years or above (1.03, 95% CI 1.00–1.05,  $p = 0.033$ ) compared to those  $\leq 69$  years [34]. 5 year survival in an equivalent Dutch trial was between 38 and 40% in those over 65 years and 54–55% in those under 65 [35], with significantly higher morbidity and mortality in those over 70 [36]. Further analysis of results from the Italian study suggested a disease-specific survival benefit for patients aged 70 years or over who had a D1 gastrectomy (75% versus 51% for D2 resection;  $p = 0.018$ ), corroborated in a further Dutch study [37]. Based on evidence from Asian countries and long-term follow-up of Western randomised trials more generally D2 resection is recommended in medically fit patients at specialist high volume centres [29,38], although this guidance is without specific consideration of older age. It is worth noting that none of these studies had pre-study criteria to establish differences in outcome with age and therefore unlikely to be powered adequately, however did carry out univariate or multivariate analyses to determine if age was an independent factor.

Certainly since the 1980s extended D2 gastric resection has been standard treatment in Japan (based on tumour location and lymph node drainage) due to significant improvements seen in survival with this technique, in the context of the high prevalence of gastric cancer in

**Table 1**  
Radical/ localised treatment approaches in the older patient.

Study / Year / Journal	Sample Size of Older Patients	Treatment	Outcome (95% CI)	Toxicity
<b>Surgery</b>				
MRC trial phase III Cuschieri et al. 1999 <i>Br J Cancer</i> [33]	N = 278; 60–69 yrs N = 324; ≥70 yrs (n = 198; < 60 yrs)	D1 vs D2 gastrectomy	Age HR 1.03 (1.01–1.04) No difference between D1 & D2 5 yr survival	Higher postoperative morbidity/ mortality in D2 gastrectomy
Italian trial phase III Degiuli et al. 2014 <i>BJS</i> [34]	N = 80; ≥70 yrs (n = 187; ≤69)	D1 vs D2 gastrectomy	HR 1.03 (1.00–1.05) p = 0.033 > 70 (vs ≤69 yrs) 5 yr DSS benefit of D1 (≥70 (75% vs 51%, p = 0.018)	No difference in morbidity/ mortality rates between D1/D2
Dutch trial phase III Bonenkamp et al. 1999 <i>NEJM</i> & Hartgrink 2004 <i>JCO</i> & Songun et al 2010 <i>Lancet</i> [35–36,38]	N = 365; > 65 yrs (n = 346; ≤65)	D1 vs D2 gastrectomy	5 yr survival 38–40% ≥65 yrs vs 54–55% < 65 HR 15 yr survival D2 vs D1 > 70 yrs 0.88 (0.67–1.16)	High postoperative morbidity 43% vs 25% (p < 0.001) and mortality 10 vs 4% (p = 0.004) in D2, higher in > 70 yrs
Italian retrospective study. Rausei et al. 2016 <i>EJSO</i> [37]	N = 636; > 70 yrs (n = 686; < 70)	D1 vs D2 gastrectomy	5 yr DSS benefit of D2 > 70 (66.6% D2 vs 57.7% D1) No survival benefit of D2 in > 70 yrs	Postoperative morbidity high in > 70 (p < 0.001), particularly after D2
Fujiwara et al. 2017 <i>World J GI Oncol</i> [39]	N = 115; > 80 yrs (n = 333; < 79)	Retrospective gastrectomies ≥80	5 yr OS 36.8% > 80 vs 68.8% < 79 (p < 0.05)	Postoperative morbidity higher > 80 (p < 0.05)
Yamada et al 2013 <i>IJS</i> [40]	N = 24; ≥85 yrs	Retrospective gastrectomies	Not assessed	Post op pneumonia high in ≥85 years (p = 0.0006)
Hsu et al. 2012 <i>J GI Surg</i> [41]	N = 164; > 80 yrs (n = 2258; < 80 yrs)	Retrospective gastrectomies	5 yr survival 44.9% > 80 vs 56.6% < 80 yr (p = 0.001) No difference in cancer-specific death	Post op morbidity higher in > 80 yrs 18.3% vs < 80 yrs 12.6% (p = 0.035)
Takeshita et al. 2013 <i>World J Surg</i> [42]	N = 104; ≥80 yrs) (n = 1089; < 80)	Retrospective gastrectomies	OS lower ≥80 yrs vs < 80 yrs p = 0.0001	Operative mortality high in ≥80 s 1.9% vs 0.7%
<b>Perioperative Treatment</b>				
Phase II FLOT65 + Lorenzen et al 2013 <i>BJC</i> [54]	N = 43; ≥65 yrs	Perioperative FLOT vs FLO	PFS 21 m FLOT vs 12 m FLO (p = 0.09) mOS not reached	More G3/4 AEs in FLOT 85.7% vs FLO 27.3%
Phase III MAGIC Trial Cunningham et al. 2006 <i>NEJM</i> [50]	N = 105; ≥70 yrs N = 186; 60–69 yrs (N = 212; < 60)	Perioperative ECF & surgery vs surgery alone	No heterogeneity in the HR for treatment effect by age p = 0.43	No significant increase in G3/4 AE with postoperative chemo after surgery
Phase III FLOT4 Al-Batran et al. 2019 <i>Lancet</i> [53]	N = 172; ≥70 yrs N = 229; 60–69 yrs (N = 315; < 60)	Perioperative ECF vs FLOT	Favoured FLOT HR 0.723 > 70 HR of 0.77 < 70 (p = 0.9402)	No difference in SAEs FLOT 27% vs 27%
<b>Adjuvant Treatment</b>				
Phase III CLASSIC trial Noh et al. 2014 <i>Lancet</i> [56]	N = 269; ≥65 yrs (n = 766; < 65 yrs)	Adjuvant CAPOX vs surgery alone	No 5 yr survival benefit in ≥65 yrs HR 0.70 (0.44–1.12) DSS benefit in ≥65 HR 0.51 (0.34–0.78)	G3/4 AE in chemo & surgery 56% vs 6% in surgery alone
Phase III ACTS-GS trial. Sakuramoto et al. 2007 <i>NEJM</i> [58]	N = 257; 70–80 yrs N = 408; 60–69 yrs (n = 394; < 60 yrs)	Adjuvant S-1 vs surgery alone	No survival benefit > 60	Most frequent G3/4 AE anorexia 6% with S-1 vs 2.1%
Phase III CRITICS trial Cats et al. 2018 <i>Lancet</i> [63]	N = 172; ≥70 yrs N = 297; 60–69 yrs (n = 319; < 60 yrs)	Postoperative chemo vs CRT	No heterogeneity in the HR for treatment effect by age ≥70 HR 0.81 OS (0.48–1.35)	Postoperative SAEs 16% both groups

AE – adverse event; D1 – limited gastrectomy; D2 extended gastrectomy; FLOT – 5-fluorouracil, oxaliplatin, docetaxel; FLO – 5-fluorouracil and oxaliplatin; ECF – epirubicin, cisplatin, 5-fluorouracil; S-1 – oral fluoropyrimidine; CAPOX – capecitabine and oxaliplatin; CRT – chemoradiotherapy; OS – overall survival; HR – hazard ratio; DSS – disease specific survival.

Asian countries and therefore increased surgical experience. However, with no significant survival benefit seen with extended gastrectomies specifically in the elderly, a more limited approach may be most appropriate [34,37] [Table 1].

Most randomised studies have restricted eligibility to those under 80 or 85, and often studies evaluating outcomes from surgical resections in elderly patients with gastric cancer have used 70 years as a cut-off. However a number of retrospective observational studies have been carried out in Asian countries reviewing octogenarians, in whom incidence is high. A retrospective study of 115 Japanese patients undergoing gastrectomies over the age of 80 compared to 333 younger patients found a significant increase in the risk of respiratory complications (6% in the ≥80 years versus 2.1% < 80, p < 0.05) and in hospital death in those over 80 (4.3% versus 0.9%, p < 0.05), as well as a reduced overall and cancer-specific survival [39]. A high incidence of post-operative pneumonia was similarly demonstrated in a study comparing post-operative respiratory outcomes in patients over

85 with those aged 75–84 years, with the former found to have lower baseline vital capacity, and therefore perhaps an indication of lower reserve capacity with age [40], in keeping with other study results [41]. However a study of 104 Japanese patients over the age of 80 who underwent curative intent gastrectomy found comparable risk of surgical complications (overall risk 29.9% versus 29.7%, p = 0.518), compared to those under 80 years, although survival was found to be lower [42]. Frequently the hesitation by surgeons to operate on the elderly is due to the perceived higher risk of complications, which with the exception of operative blood loss was found to be no different in this study. The same author group reviewed patients from multiple centres with a higher cut-off of age ≥85 and found gastrectomy with radical lymphadenectomy an effective and acceptable treatment in this cohort [43]. However the average frequency of these patients over 85 years treated with surgery was deemed to be low, between 2.2 and 3.8% in the multiple centres included, therefore the number of cases in this study was small. Overall there has been significant variability in study

outcomes and risk of complications amongst the older age group, particularly in retrospective observational studies. Therefore the individual assessment of patient fitness and pre-operative morbidity is clearly most important prior to consideration of surgery. Most of these studies did not identify functional age as a measure of frailty, with varying cut-offs of chronological age used as a determinant of appropriateness for surgery, which as demonstrated, do not consistently indicate risks of complication or survival benefit in older patients with gastric cancer, even in those patients over 80 years old.

Survival outcomes in randomised data appear similar between laparoscopic versus open gastrectomy [44], however minimally invasive surgery is generally considered to have fewer postoperative complications and morbidity [45], and is a recommended option for certain patients with early stage cancer [29]. Randomised data of laparoscopic surgery has predominantly been carried out in a younger age group, and therefore extrapolation of trial results for older patients is more difficult. However a number of smaller Asian observational studies have demonstrated an advantage of minimally invasive surgery with regards to improved recovery time and surgical complication rates [46–49]. Therefore it may prove to be a more suitable technique for the older age group who may have a more limited functional reserve and at a higher risk of complications.

#### Perioperative chemotherapy

Survival of patients with locally advanced gastric cancer treated with radical surgery remains poor due to a high rate of relapse. A number of randomised trials have evaluated the role of perioperative chemotherapy in addition to surgery in this setting, demonstrating a significant survival benefit [50–53]. However concerns remain regarding treatment with chemotherapy in the elderly due to risks of perioperative morbidity from toxicity. To determine the feasibility of treating patients over the age of 65, a predefined exploratory subgroup analysis of patients within the randomised phase II FLOT 65+ trial compared patients treated with perioperative FLOT (5-fluorouracil (5-FU), oxaliplatin and docetaxel) or FLO (without docetaxel) [54]. A high level of adherence was found, with 85% of patients receiving all 4 pre-operative cycles of FLOT, and no clinically significant increase in grade 3–4 toxicity postoperatively. Mortality and morbidity rates were comparable to that of the UK MRC Adjuvant Gastric Infusional Chemotherapy (MAGIC) and Fédération Francophone de Cancérologie Digestive (FFCD) trials, which were performed in patients of all ages, however only 75% of patients enrolled underwent surgical resection as planned (although of these only 2/11 (18%) were due to toxicity or death). Neoadjuvant FLO or FLOT chemotherapy is therefore a reasonable option in elderly patients with locally advanced resectable gastroesophageal cancer.

In addition to the effect of perioperative chemotherapy on toxicity, randomised trial evidence does not appear to show a detrimental effect on survival outcomes based on age. The MAGIC trial compared 3 cycles of pre and postoperative ECF (epirubicin, cisplatin, 5-FU) chemotherapy with surgery alone, with no heterogeneity in the hazard ratio (HR) for treatment effect by age, including in those over 70 [50]. Similarly the phase III FLOT4 trial (comparing ECF with FLOT chemotherapy perioperatively) showed a consistent relative treatment effect with relation to age, favouring FLOT, with a HR of 0.77 in those under 60 versus HR 0.723 in those patients over 70 ( $p = 0.9402$ ) [53]. Age related effects were not reported in the phase III randomised CROSS trial, comparing pre-operative chemoradiotherapy with surgery compared to surgery alone in oesophageal or oesophago-gastric junctional cancers, and eligibility was capped to an upper limit of 75 years of age [55].

Based on this evidence it would be reasonable to treat elderly patients with locally advanced gastric or oesophageal cancer with both perioperative chemotherapy and radical surgery. Although most trials had no upper age limit to eligibility, it is possible that older patients

selected to participate were generally fit with a good baseline functional status, and therefore an individualised approach to selecting patients should be adopted to minimise the likelihood of toxicity.

#### Adjuvant chemotherapy

In patients with resected gastric cancer staged IB and above, who have not received preoperative chemotherapy, adjuvant treatment with chemotherapy or postoperative chemoradiotherapy is recommended [29]. Regardless of age, morbidity is relatively high following radical surgery, and careful thought ought to be given to those deemed most appropriate for ongoing adjuvant treatment.

The CLASSIC trial, an Asian study of 6 months of adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in 520 patients compared to surgery alone in 515 patients, was overall suggestive of a significant benefit of chemotherapy after surgery. Subgroup analysis by age showed a significant benefit from adjuvant chemotherapy in 5 year overall survival in those 766 patients aged under 65 years (HR 0.67, 95% CI 0.50–0.91), however significance was lost in those 269 patients over 65 years (HR 0.70, 95% CI 0.44–1.12) [56]. Disease free survival was improved in both age groups. The feasibility or toxicity of treatment with adjuvant chemotherapy was not assessed in the older age group [57]. The Japanese Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GS) similarly showed no advantage of S-1 (oral fluoropyrimidine) in overall or relapse-free survival in patients aged 70–80, although a clear benefit in those patients younger than 60 [58].

Although a meta-analysis of individual patient data from 17 randomised trials (including 3838 patients), comparing adjuvant chemotherapy with surgery alone, suggested an overall benefit in terms of survival (HR 0.82, 95% CI 0.76–0.9), the applicability of these results in Europe remains uncertain, as most studies in this setting were performed in Asia [59]. Generally adjuvant chemotherapy is less well tolerated than neoadjuvant chemotherapy, and certainly in the older patient with resectable gastric cancer, perioperative chemotherapy may be a preferential option, or careful consideration given to those who have not received preoperative chemotherapy.

#### Adjuvant chemoradiotherapy

In the US, adjuvant chemoradiotherapy after surgery is considered standard treatment, based on results of the South Western Oncology Group (SWOG)-Directed Intergroup Study 0116. This phase III trial of adjuvant chemoradiotherapy after surgery versus observation demonstrated a significant survival benefit, maintained after 10 years of follow-up, with age of included patients ranging from 23 to 87 [60]. However no age specific subgroup analysis was performed to determine if benefit persisted in the older age group. Review of more than 8000 US gastric cancer patients has shown that although 61% of resections occur in patients over 65 years only a minority proceeded to adjuvant radiotherapy [61]. In Europe adjuvant chemoradiotherapy hasn't yet been adopted due to concerns regarding late toxicity from radiotherapy and insufficiently extensive surgery carried out in a significant proportion of patients within the Intergroup 0116 trial [29]. In a subset of higher risk patients, adjuvant chemoradiotherapy may prove beneficial, as demonstrated in the ARTIST trial of radiotherapy with or without cisplatin and capecitabine [62]. Although recurrence rates were not reduced after curative resection with radiotherapy, a significant benefit was seen in those with lymph node metastases, however the higher rates of hand-foot syndrome and neutropenia may be relevant when considering treatment in the older age group. The more recent European CRITICS trial of chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer showed no additional benefit of postoperative chemoradiotherapy versus postoperative chemotherapy with regards to overall survival (hazard ratio from stratified analysis 1.01, 95% CI 0.84–1.22). Compliance was poor in both groups, and postoperative toxicity similar,

**Table 2**  
Summary of trials of the treatment of metastatic/advanced gastric cancer in older patients.

Study / Year / Journal	Sample Size of Older Patients	Chemotherapy	Outcome (95% CI)	G3/4 Toxicity
GO2 (phase III) Hall et al. <i>JCO</i> Hall et al., 2019;37 [76–77]; Hall et al., 2019;30.	N = 514 Elderly +/- frail	Oxaliplatin & Capecitabine Standard dose (A): 80% (B): 60% (C)	Non-inferiority of PFS HR 1.10 (0.90–1.33) of C vs A mOS 7.5 m(A):6.7 m(B):7.6 m(C)	Abstract only
Meta-analysis REAL-2 & ML17032 Okines et al. 2009 <i>Annals of Onc</i> [66]	N = 731; ≥60 years (N = 582; < 60 years)	Capecitabine combination vs 5-FU combination	OS HR 0.83 (0.73–0.94) benefit in ≥60 years	Not reported
Trumper et al. 2006 pooled analysis 3 trials <i>EJC</i> [71]	N = 257; ≥70 N = 823; < 70	ECF vs PVI 5-FU vs FAMTX	Effect of age on OS HR 1.068 (0.97–1.271); 1 year OS 35% (both cohorts)	No significant difference ≥70 vs < 70
Hwang et al. 2017 (Phase III) <i>J Geriatr Oncol</i> [75]	N = 50; ≥70	Capecitabine vs XELOX	mOS 11.1 m XELOX vs 6.3 m Capecitabine HR 0.58 (0.30–1.12)	Most frequent G3/4 toxicity fatigue < 13%
ToGA (phase III) Bang et al. 2010 <i>The Lancet</i> [81]	N = 305 ≥ 60 years (n = 279 < 60)	Cisplatin + 5FU or Cape +/- Trastuzumab	< 60 yrs HR for OS 0.84 (0.62–1.14) ≥60 yrs HR 0.66 (0.49–0.88)	201 (68%) Trastuzumab 198 (68%) Chemo
FLOT65+ (phase II) Al-Batran et al. 2013 <i>EJC</i> [72]	N = 143 ≥ 65 years	FLOT vs FLO	No benefit ORR in metastatic (FLOT 44%, FLO 32.7%, p = 0.303) & ≥70 s (FLOT 32.4%, FLO 31.7%, p = 1.0)	81.9% FLOT 38.6% FLO
miniDOX (phase II) 2015 Rivera et al. <i>Cancer Chemother Pharmacol</i> [74]	N = 43 ≥70 years PS ECOG = 2 wt loss 10–25%	Reduced dose DOX	mOS 13.3 months 1 year OS 52%	N = 32 (76.2%)
Catalano et al. (phase II) 2013 <i>Gastric Cancer</i> [80]	N = 43 ≥70 years	Modified FOLFOX	ORR 34.9% (20.6–49.1) mOS 10.5 m mPFS 6.8 m	N = 13 (30.2%)
Xiang et al. 2012 (Phase II) <i>Chemotherapy</i> [79]	N = 46 ≥70	Capecitabine & Oxaliplatin	ORR 48.9% mOS 10.0 m (8.6–11.4) mTTP 6.0 m (3.9–8.1)	Most frequent toxicity leukocytopenia 5 (10.8%)
Lee et al 2008 (phase II) <i>BJC</i>	N = 96 ≥65 years	Capecitabine vs S-1	ORR 26.1% vs 28.9%; mOS 9.5 vs 8.2 months; 1 year OS 30.2% vs 27.3%; mTTP 4.7 m vs 4.2 m	Most frequent G3/4 toxicity anaemia (11.4% vs 14.3%)

PVI 5FU – protracted venous infusion of 5-fluorouracil +/- mitomycin C; FAMTX – 5-fluorouracil, doxorubicin + methotrexate; DOX – docetaxel oxaliplatin capecitabine; FLOT – 5-fluorouracil oxaliplatin docetaxel; FLO – 5-fluorouracil oxaliplatin; XELOX – capecitabine and oxaliplatin; FOLFOX – 5-fluorouracil and oxaliplatin; OS – overall survival; PFS – progression free survival; TTP – time to progression; RR – relative risk.

with no clear evidence of heterogeneity of treatment effect by age [63], and results have been replicated in another retrospective study of patients over 65 years [64]. It's likely that the predominant survival benefit comes from preoperative treatment, and perhaps should be prioritised over postoperative treatment in older patients, although more age specific prospective studies are required to better understand the adjuvant treatment requirements of the elderly [Table 1].

### The management of the older patient with gastric cancer in the metastatic setting

#### Palliative chemotherapy

In fit patients with inoperable advanced or metastatic gastric cancer doublet or triplet platinum/fluoropyrimidine chemotherapy combinations are recommended first line [29,65–70]. There have been a few studies specifically evaluating the safety and efficacy of treatment of the elderly patient in this setting [Table 2]. Using data from 3 large randomised trials, one retrospective analysis of 1080 patients with gastro-oesophageal cancer compared those over the age of 70 years (n = 257) with younger patients on fluorouracil-based combination regimens [71]. Response rates, overall survival and incidence of grade 3 or 4 toxicity were similar between the two age cohorts, suggesting patients over 70 gained a similar benefit to systemic chemotherapy to younger patients. However clinician bias in determining appropriate eligibility for trial candidates may explain these findings. No octogenarians were included in this study and patients over 70 received a lower dose intensity of chemotherapy, as such results suggesting an absence of increased toxicity with age should be interpreted with caution [71].

The FLOT65+ study of triple drug chemotherapy in 143 patients

with a median age of 70 showed a lack of benefit of triplet (FLOT) chemotherapy over the doublet (FLO) combination with regards to response rate or progression-free survival (PFS) in patients with metastatic disease or in the subgroup over 70 years, unlike the 65–70 year age group or those with locally advanced disease [72]. Despite a similar toxicity profile seen in the over and under 70 groups between both treatments, a significant deterioration in quality of life was demonstrated in patients on FLOT. The phase II miniDOX trial of reduced dose triplet regime, docetaxel, oxaliplatin and capecitabine, in advanced gastric cancer patients considered 'suboptimal' (defined as age ≥70, performance status 2 or weight loss of 10–25%) showed a comparable response rate to the equivalent phase II GATE study in good prognostic groups [73], however the toxicity profile was significant [74].

To determine the optimum number of agents for elderly patients, single agent capecitabine was compared to capecitabine and oxaliplatin (XELOX), in a Korean phase III trial of individuals over 70 with gastric cancer [75]. The platinum-based doublet regime was associated with an overall and progression-free survival benefit, with an acceptable toxicity profile seen. The recent UK GO2 phase III trial evaluated the optimum dose of oxaliplatin and capecitabine in 514 frail, elderly patients, with a median age of 76 and deemed unsuitable for full dose triplet chemotherapy [76]. They demonstrated that the lowest dose level (60% dose), versus 80% and standard dose, was non-inferior for PFS (lowest dose versus standard HR 1.10, 95% CI 0.90–1.33), with patients experiencing less toxicity and better overall treatment utility (considered a composite of clinical benefit, tolerability, quality of life, and patient value). This study is the largest randomised trial to date in elderly patients with gastro-oesophageal cancer, demonstrating that a lower dose of treatment does not compromise on disease control or survival, together with better quality of life [77].

Other smaller phase II studies have also specifically looked at fluorouracil with reduced dose oxaliplatin (modified FOLFOX), reduced dose capecitabine with oxaliplatin (CAPOX) and single agent capecitabine versus S1 in elderly patients, suggesting single agent treatment, or modified dose double agent chemotherapy would be tolerable options for first line treatment [78–80].

Trastuzumab in combination with chemotherapy has been demonstrated in the Trastuzumab for Gastric Cancer (ToGA) trial to provide survival benefit in advanced HER2-positive gastro-oesophageal cancer [81]. Median overall survival was 13.8 months (95% CI 12–16) in those individuals on trastuzumab, versus 11.1 months (95% CI 10–13) in those on chemotherapy alone. Subgroup analysis of the effect of age showed an advantage in those on trastuzumab ≥60 years (HR 0.66, 95% CI 0.49–0.88) compared to ≤60 years (HR 0.84, 95% CI 0.62–1.14). However little other evidence is available directly assessing the effects of targeted treatment trastuzumab in the older cancer patient.

In patients over 70 with metastatic disease, it may be most appropriate to consider treatment with two-drug chemotherapy regimens, and to consider dose reduced therapy, in the context of an individual's functional age, for an optimum survival advantage equivalent to younger patients [Fig. 1: Proposed treatment algorithm of gastric cancer in the older patient [29]].

**Palliative surgery**

Currently there is little evidence of a role for palliative resection in gastric cancer. The phase III REGATTA trial of 175 patients with incurable gastric cancer, randomised to palliative chemotherapy alone or gastrectomy with chemotherapy showed no survival advantage of surgery, with median OS 16.6 months (95% CI 13.7–19.8) with chemotherapy versus 14.3 months (95% CI 11.8–16.3) with surgery and chemotherapy [82]. Patients included within the trial had an age range of 49–67, and therefore it did not adequately represent older adults. Regardless of this, palliative gastrectomy or metastatectomy should not be considered in patients with advanced gastric cancer, unless further evidence suggests a potential benefit [29]

**Clinical trials – are we justified in using age restrictive criteria?**

A number of studies have demonstrated that the proportion of older patients recruited into clinical trials has been significantly less than expected based on the high prevalence of older patients in the cancer population [83]. Chronological age should not be an exclusive reason to underrepresent the elderly in clinical trials, which has been a significant issue in the past [83]. It has become more evident that elderly patients may need a modified approach to treatment, based on their fitness and levels of frailty, however this requires evidence-based guidance. There has been an increasing focus on geriatric oncology in the last decade, particularly since the development of The International Society of Geriatric Oncology in 2000. A review of 1084 clinical trials from 2001 to 2014 demonstrated a tripling of subgroup analyses of elderly patients in phase III trials, but also a significant increase in phase I and II trials dedicated to elderly patients [84]. One such study of 1004 patients treated in 30 phase I trials, which have strict inclusion criteria and often test agents which are first-in-man, demonstrated that the toxicity profile was independent of age, and comparable response and survival outcomes were seen in those patients over 65 years and those below [85]. An increase in the inclusion of elderly patients within phase I trials is of course an important improvement, however the lack of sufficient representation in dedicated phase III trials limits the generalisability of these results to the general older population [84]. Frequently clinical trials have restricted inclusion to an upper age limit of 75, and although this has been less common in more recent trials, concerns about increased risk of toxicity in the elderly continue to limit participation [86]. The European Organisation for Research and Treatment of Cancer (EORTC)'s Elderly Task Force was established to improve access to research for older people with cancer, to provide the evidence base for management decisions in this cohort of patients [87]. Guidelines have since been published requiring clinical trials to be without an upper age limit for inclusion and a more standardised approach to measuring frailty in clinical trials has been recommended [88]. Low grade toxicity may have more clinical significance in older patients, with regards to treatment modification or discontinuation, and clinical trials should reflect this when reporting outcomes [89]. More well designed randomised controlled trials, like the GO2 phase III trial, in the older population are required in the setting of gastric cancer to




Fig. 1. Proposed treatment algorithm of gastric cancer in the older patient based on current guidelines [29].

specifically address the age related changes in pharmacokinetics and pharmacodynamics, and variability in functional status, using low-toxicity interventions more relevant and acceptable to this cohort.

### Future directions and conclusion

Older patients continue to be underrepresented in clinical trials, and concerns remain amongst clinicians, particularly in gastric cancer where morbidity is high, regarding inclusion of patients in randomised clinical trials. Individuals currently entered into trials tend to be fitter, with fewer co-morbidities, and perhaps better prognostic disease, and therefore may not accurately represent the older general population. As demonstrated by the evidence in this review, elderly patients have been shown to have the same advantages from radical treatment and palliative chemotherapy as younger patients, however an individualised approach to treatment decisions is required to improve outcomes in this cohort [Fig. 1]. Use of a geriatric assessment is a feasible method of screening for frail patients, to optimise treatment decision based on functional age rather than chronological age.

### Authors Contributions

All the authors approved the manuscript.

### Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### CRedit authorship contribution statement

**Nalinie Joharatnam-Hogan:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing. **Kai Keen Shiu:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing. **Khurum Khan:** Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing.

### Declaration of Competing Interest

All authors have declared no conflicts of interest.

### References

- Maddams J, Utley M, Moller H. Projections of cancer prevalence in the United Kingdom, 2010–2040. *Br J Cancer* 2012;107(7):1195–202.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68(6):394–424.
- Etemadi A, Safiri S, Sepanlou SG, Ikuta K, Bisignano C, Shakeri R, et al. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. *Lancet Gastroenterol Hepatol* 2020.
- Cancer Research UK. <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/stomach-cancer>. Accessed Nov 2019.
- Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. *The Lancet* 2011;377(9760):127–38.
- Gaitonde SG, Fischer TD, Jones MS, Bandera B, Stern S, Goldfarb M. Young age, disparities, and survival in gastric adenocarcinoma: Implications for screening strategies. *J Clin Oncol* 2017;35(4, suppl):17.
- Liang Y-X, Deng J-Y, Guo H-H, Ding X-W, Wang X-N, Wang B-G, et al. Characteristics and prognosis of gastric cancer in patients aged  $\geq 70$  years. *World J Gastroenterol* 2013;19(39):6568–78.
- Medina-Franco H, Heslin MJ, Cortes-Gonzalez R. Clinicopathological characteristics of gastric carcinoma in young and elderly patients: a comparative study. *Ann Surg Oncol* 2000;7(7):515–9.
- Kim DY, Joo JK, Ryu SY, Park YK, Kim YJ, Kim SK. Clinicopathologic characteristics of gastric carcinoma in elderly patients: a comparison with young patients. *World J Gastroenterol* 2005;11(1):22–6.
- Arai T, Esaki Y, Inoshita N, Sawabe M, Kasahara I, Kuroiwa K, et al. Pathologic characteristics of gastric cancer in the elderly: a retrospective study of 994 surgical patients. *Gastric Cancer: Off J Int Gastric Cancer Assoc Japanese Gastric Cancer Assoc* 2004;7(3):154–9.
- Kitamura K, Yamaguchi T, Taniguchi H, Hagiwara A, Yamane T, Sawai K, et al. Clinicopathological characteristics of gastric cancer in the elderly. *Br J Cancer* 1996;73(6):798–802.
- Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: Classification, histology and application of molecular pathology. *J Gastrointestinal Oncol* 2012;3(3):251–61.
- Saif W, Makrilla N, Zalonis A, Merikas M, Syrigos K. Gastric cancer in the elderly: An overview. *Eur J Surg Oncol* 2010;36(8):709.
- Balducci L. Systemic treatment of gastric and esophageal adenocarcinoma in elderly patients. *J Gastrointestinal Oncol* 2014;6(1):75–8.
- Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies in older adults. *Br J Cancer* 2008;98(3):517–22.
- Shahroki A, Kim SJ, Bosl GJ, Korc-Grodzicki B. How we care for an older patient with cancer. *J Oncol Practice* 2017;13(2):95–102.
- Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. *J Clin Oncol* 2007;25(14):1824–31.
- Korc-Grodzicki B, Holmes HM, Shahroki A. Geriatric assessment for oncologists. *Cancer Biol Med* 2015;12(4):261–74.
- Chaibi P, Magne N, Breton S, Chebib A, Watson S, Duron JJ, et al. Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. *Crit Rev Oncol/Hematol* 2011;79(3):302–7.
- Girre V, Falcou MC, Gisselbrecht M, Gridel G, Mosseri V, Bouleuc C, et al. Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients? *J Gerontol A Biol Sci Med Sci* 2008;63(7):724–30.
- Luciani A, Ascione G, Bertuzzi C, Marussi D, Codeca C, Di Maria G, et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. *J Clin Oncol* 2010;28(12):2046–50.
- Saliba DEM, Rubenstein LZ, Solomon DH, Young RT, Kamberg CJ, Roth C, et al. The vulnerable elders survey: a tool for identifying vulnerable older people in the community. *J Am Geriatr* 2001;49(12).
- Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. *Ann Oncol* 2012;23(8):2166–72.
- Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. *J Clin Oncol* 2014;32(24):2595–603.
- Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. *Ann Oncol* 2015;26(2):288–300.
- Xue D-D, Cheng Y, Wu M, Zhang Y. Comprehensive geriatric assessment prediction of postoperative complications in gastrointestinal cancer patients: a meta-analysis. *Clin Interv Aging* 2018;13:723–36.
- Rostoft S. Integration of geriatric assessment in the care of patients with gastrointestinal malignancies. *Visceral Med* 2017;33(4):275–80.
- Pujara D, Mansfield P, Ajani J, Blum M, Elimova E, Chiang YJ, et al. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. *J Surg Oncol* 2015;112(8):883–7.
- Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol* 2016;27(suppl\_5):v38–49.
- Lin JX, Huang YQ, Xie JW, Wang JB, Lu J, Chen QY, et al. Age-adjusted Charlson Comorbidity Index (ACCI) is a significant factor for predicting survival after radical gastrectomy in patients with gastric cancer. *BMC Surg* 2019;19(1):53.
- Kurita N, Miyata H, Gotoh M, Shimada M, Imura S, Kimura W, et al. Risk model for distal gastrectomy when treating gastric cancer on the basis of data from 33,917 Japanese patients collected using a nationwide web-based data entry system. *Ann Surg* 2015;262(2):295–303.
- Watanabe M, Miyata H, Gotoh M, Baba H, Kimura W, Tomita N, et al. Total gastrectomy risk model: data from 20,011 Japanese patients in a nationwide internet-based database. *Ann Surg* 2014;260(6):1034–9.
- Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. *Br J Cancer* 1999;79(9–10):1522–30.
- Degliuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. *BJS (British J Surg)* 2014;101(2):23–31.
- Bonenkamp JJ, Hermans J, Sasako M, Welvaart K, Songun I, Meyer S, et al. Extended lymph-node dissection for gastric cancer. *N Engl J Med* 1999;340(12):908–14.
- Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenburg E, Songun I, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. *J Clin Oncol*

- 2004;22(11):2069–77.
- [37] Rausei S, Ruspi L, Rosa F, Morgagni P, Marrelli D, Cossu A, et al. Extended lymphadenectomy in elderly and/or highly co-morbid gastric cancer patients: A retrospective multicenter study. *Euro J Surg Oncol (EJSO)* 2016;42(12):1881–9.
- [38] Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. *Lancet Oncol* 2010;11(5):439–49.
- [39] Fujiwara Y, Fukuda S, Tsujie M, Ishikawa H, Kitani K, Inoue K, et al. Effects of age on survival and morbidity in gastric cancer patients undergoing gastrectomy. *World J Gastrointest Oncol* 2017;9(6):257–62.
- [40] Yamada H, Shinohara T, Takeshita M, Umesaki T, Fujimori Y, Yamagishi K. Postoperative complications in the oldest old gastric cancer patients. *Int J Surg* 2013;11(6):467–71.
- [41] Hsu J-T, Liu M-S, Wang F, Chang C-J, Hwang T-L, Jan Y-Y, et al. Standard radical gastrectomy in octogenarians and nonagenarians with gastric cancer: are short-term surgical results and long-term survival substantial? *J Gastrointestinal Surg* 2012;16(4):728–37.
- [42] Takeshita H, Ichikawa D, Komatsu S, Kubota T, Okamoto K, Shiozaki A, et al. Surgical outcomes of gastrectomy for elderly patients with gastric cancer. *World J Surg* 2013;37(12):2891–8.
- [43] Konishi H, Ichikawa D, Itoh H, Fukuda K, Kakahara N, Takemura M, et al. Surgery for gastric cancer patients of age 85 and older: Multicenter survey. *World J Gastroenterol* 2017;23(7):1215–23.
- [44] Yu J, Huang C, Sun Y, Su X, Cao H, Hu J, et al. Effect of Laparoscopic vs Open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial. *JAMA* 2019;321(20):1983–92.
- [45] Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for Stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). *Ann Surg* 2016;263(1):28–35.
- [46] Inokuchi M, Tanioka T, Nakagawa M, Okuno K, Gokita K, Kojima K. Laparoscopic distal gastrectomy is feasible in very elderly patients as compared with open distal gastrectomy. *J Invest Surg* 2018;31(6):539–45.
- [47] Yasuda K, Sonoda K, Shiroshita H, Inomata M, Shiraishi N, Kitano S. Laparoscopically assisted distal gastrectomy for early gastric cancer in the elderly. *Br J Surg* 2004;91(8):1061–5.
- [48] Kwon IG, Cho I, Guner A, Kim HI, Noh SH, Hyung WJ. Minimally invasive surgery as a treatment option for gastric cancer in the elderly: comparison with open surgery for patients 80 years and older. *Surg Endosc* 2015;29(8):2321–30.
- [49] Liu C-A, Huang K-H, Chen M-H, Lo S-S, Li AF-Y, Wu C-W, et al. Comparison of the surgical outcomes of minimally invasive and open surgery for octogenarian and older compared to younger gastric cancer patients: a retrospective cohort study. *BMC Surg* 2017;17(1):68.
- [50] Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355(1):11–20.
- [51] Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *J Clin Oncol* 2011;29(13):1715–21.
- [52] Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. *Ann Oncol* 2008;19(10):1720–6.
- [53] Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet* 2019;393(10184):1948–57.
- [54] Lorenzen S, Pauligk C, Homann N, Schmalenberg H, Jäger E, Al-Batran SE. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. *Br J Cancer* 2013;108(3):519–26.
- [55] van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MIVB, Wijnhoven BPL, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. *New Engl J Med* 2012;366(22):2074–84.
- [56] Noh SH, Park SR, Yang H-K, Chung HC, Chung I-J, Kim S-W, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol* 2014;15(12):1389–96.
- [57] Bang Y-J, Kim Y-W, Yang H-K, Chung HC, Park Y-K, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. *The Lancet* 2012;379(9813):315–21.
- [58] Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med* 2007;357(18):1810–20.
- [59] The GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer: A Meta-analysis. *JAMA* 2010;303(17):1729–37.
- [60] Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. *J Clin Oncol* 2012;30(19):2327–33.
- [61] Dudgey V, Habermann EB, Zhong W, Tuttle TM, Vickers SM, Jensen EH, et al. Guideline recommended gastric cancer care in the elderly: insights into the applicability of cancer trials to real world. *Ann Surg Oncol* 2011;18(1):26–33.
- [62] Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. *J Clin Oncol* 2011;30(3):268–73.
- [63] Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordmark M, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. *Lancet Oncol* 2018;19(5):616–28.
- [64] Karaca M, Tural D, Kocoglu H, Selcukbiricik F, Bilgetekin I, et al. Adjuvant chemotherapy for gastric cancer in elderly patients has same benefits as in younger patients. *J Cancer Res Ther* 2018;14(3):593–6.
- [65] Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study—FFCD 9803. *J Clin Oncol* 2004;22(21):4319–28.
- [66] Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. *Ann Oncol* 2009;20(9):1529–34.
- [67] Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* 2008;358(1):36–46.
- [68] Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 2006;24(31):4991–7.
- [69] Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2008;19(11):1882–7.
- [70] Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andre T, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. *J Clin Oncol* 2014;32(31):3520–6.
- [71] Trumper M, Ross PJ, Cunningham D, Norman AR, Hawkins R, Seymour M, et al. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. *Eur J Cancer* 2006;42(7):827–34.
- [72] Al-Batran SE, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). *Eur J Cancer* 2013;49(4):835–42.
- [73] Van Cutsem E, Boni C, Taberner J, Massuti B, Middleton G, Dane F, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. *Ann Oncol* 2015;26(1):149–56.
- [74] Rivera F, Massuti B, Salcedo M, Sastre J, Martínez Galán J, Valladares-Ayerbes M, et al. Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). *TTD 08–02. Cancer Chemother Pharmacol* 2015;75(2):319–24.
- [75] Hwang IG, Ji JH, Kang JH, Lee HR, Lee HY, Chi KC, et al. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. *J Geriatr Oncol* 2017;8(3):170–5.
- [76] Hall PS, Swinson D, Waters JS, Wadley J, Falk S, Roy R, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. *J Clin Oncol* 2019;37(15\_suppl):4006.
- [77] Hall P, Swinson D, Lord S, Handforth C, Cairns D, Marshall H, et al. LBA46Chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): Quality of Life (QoL) results from the GO2 phase III trial. *Ann Oncol* 2019;30(Supplement\_5).
- [78] Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. *Br J Cancer* 2008;99(4):584–90.
- [79] Xiang XJ, Zhang L, Qiu F, Yu F, Zhan ZY, Feng M, et al. A Phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer. *Chemotherapy* 2012;58(1):1–7.
- [80] Catalano V, Bissonni R, Graziano F, Giordani P, Alessandrini P, Baldelli AM, et al. A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases. *Gastric Cancer: Off J Int Gastric Cancer Assoc Japanese Gastric Cancer Assoc* 2013;16(3):411–9.
- [81] Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *The Lancet* 2010;376(9742):687–97.
- [82] Fujitani K, Yang H-K, Mizusawa J, Kim Y-W, Terashima M, Han S-U, et al. Gastric cancer plus chemotherapy versus chemotherapy alone for advanced gastric

- cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. *Lancet Oncol* 2016;17(3):309–18.
- [83] Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. *N Engl J Med* 1999;341(27):2061–7.
- [84] Le Saux O, Falandry C, Gan HK, You B, Freyer G, Péron J. Inclusion of elderly patients in oncology clinical trials. *Ann Oncol* 2016;27(9):1799–804.
- [85] Khan KH, Yap TA, Ring A, Molife LR, Bodla S, Thomas K, et al. Phase I trial outcomes in older patients with advanced solid tumours. *Br J Cancer* 2016;114(3):262–8.
- [86] Ring A, Harari D, Kalsi T, Mansi J, Selby P. *Problem Solving in Older Cancer Patients*. 1st ed. Oxford: Clinical Publishing; 2015.
- [87] Pallis AG, Ring A, Fortpied C, Penninckx B, Van Nes MC, Wedding U, et al. EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. *Ann Oncol* 2011;22(8):1922–6.
- [88] Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A, et al. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer–Alliance for Clinical Trials in Oncology–International Society Of Geriatric Oncology position article. *J Clin Oncol* 2013;31(29):3711–8.
- [89] Kalsi T, Babic-Illman G, Fields P, Hughes S, Maisey N, Ross P, et al. The impact of low-grade toxicity in older people with cancer undergoing chemotherapy. *Br J Cancer* 2014;111(12):2224–8.